BACKGROUND. Mortality is very high in lactic acidosis, and there is no satisfactory treatment other than treatment of the underlying cause. Uncontrolled studies have suggested that dichloroacetate, which stimulates the oxidation of lactate to acetyl-coenzyme A and carbon dioxide, might reduce morbidity and improve survival among patients with this condition. METHODS. We conducted a placebo-controlled, randomized trial of intravenous sodium dichloroacetate therapy in 252 patients with lactic acidosis; 126 were assigned to receive dichloroacetate and 126 to receive placebo. The entry criteria included an arterial-blood lactate concentration of > or = 5.0 mmol per liter and either an arterial-blood pH of < or = 7.35 or a base deficit of > or = 6 mmol per liter. The mean (+/- SD) arterial-blood lactate concentrations before treatment were 11.6 +/- 7.0 mmol per liter in the dichloroacetate-treated patients and 10.4 +/- 5.5 mmol per liter in the placebo group, and the mean initial arterial-blood pH values were 7.24 +/- 0.12 and 7.24 +/- 0.13, respectively. Eighty-six percent of the patients required mechanical ventilation, and 74 percent required pressor agents, inotropic drugs, or both because of hypotension. RESULTS. The arterial-blood lactate concentration decreased 20 percent or more in 83 (66 percent) of the 126 patients who received dichloroacetate and 45 (36 percent) of the 126 patients who received placebo (P = 0.001). The arterial-blood pH also increased more in the dichloroacetate-treated patients (P = 0.005). The absolute magnitude of the differences was small, however, and they were not associated with improvement in hemodynamics or survival. Only 12 percent of the dichloroacetate-treated patients and 17 percent of the placebo patients survived to be discharged from the hospital. CONCLUSIONS. Dichloroacetate treatment of patients with severe lactic acidosis results in statistically significant but clinically unimportant changes in arterial-blood lactate concentrations and pH and fails to alter either hemodynamics or survival.
Source Information
Department of Medicine, University of Florida College of Medicine, Gainesville.
This article has been cited by other articles:
Phypers, B., Pierce, J. T.
(2006). Lactate physiology in health and disease. Contin Educ Anaesth Crit Care Pain
6: 128-132
[Full Text]
Kaufmann, P., Engelstad, K., Wei, Y., Jhung, S., Sano, M. C., Shungu, D. C., Millar, W. S., Hong, X., Gooch, C. L., Mao, X., Pascual, J. M., Hirano, M., Stacpoole, P. W., DiMauro, S., De Vivo, D. C.
(2006). Dichloroacetate causes toxic neuropathy in MELAS: A randomized, controlled clinical trial. Neurology
66: 324-330
[Abstract][Full Text]
Fall, P. J., Szerlip, H. M.
(2005). Lactic Acidosis: From Sour Milk to Septic Shock. J Intensive Care Med
20: 255-271
[Abstract]
English, P, Williams, G
(2004). Hyperglycaemic crises and lactic acidosis in diabetes mellitus. Postgrad. Med. J.
80: 253-261
[Abstract][Full Text]
Duncan, G. E., Perkins, L. A., Theriaque, D. W., Neiberger, R. E., Stacpoole, P. W.
(2004). Dichloroacetate Therapy Attenuates the Blood Lactate Response to Submaximal Exercise in Patients with Defects in Mitochondrial Energy Metabolism. J. Clin. Endocrinol. Metab.
89: 1733-1738
[Abstract][Full Text]
Stacpoole, P. W., Nagaraja, N. V., Hutson, A. D.
(2003). Efficacy of Dichloroacetate as a Lactate-Lowering Drug. J Clin Pharmacol
43: 683-691
[Abstract][Full Text]
Kumar, A., Nugent, K., Kalakunja, A., Pirtle, F.
(2003). Severe Acidosis in a Patient With Type 2 Diabetes Mellitus, Hypertension, and Renal Failure. Chest
123: 1726-1729
[Full Text]
CIUFO, R., DIMARCO, A., STOFAN, D., NETHERY, D., SUPINSKI, G.
(2001). Dichloroacetate Reduces Diaphragmatic Lactate Formation But Impairs Respiratory Performance. Am. J. Respir. Crit. Care Med.
164: 1669-1674
[Abstract][Full Text]
Krishna, S., Nagaraja, N. V., Planche, T., Agbenyega, T., Bedo-Addo, G., Ansong, D., Owusu-Ofori, A., Shroads, A. L., Henderson, G., Hutson, A., Derendorf, H., Stacpoole, P. W.
(2001). Population Pharmacokinetics of Intramuscular Quinine in Children with Severe Malaria. Antimicrob. Agents Chemother.
45: 1803-1809
[Abstract][Full Text]
Smolenski, R. T., Amrani, M., Jayakumar, J., Jagodzinski, P., Gray, C. C., Goodwin, A. T., Sammut, I. A., Yacoub, M. H.
(2001). Pyruvate/dichloroacetate supply during reperfusion accelerates recovery of cardiac energetics and improves mechanical function following cardioplegic arrest. Eur. J. Cardiothorac. Surg.
19: 865-872
[Abstract][Full Text]
White, A. J
(2001). Mitochondrial toxicity and HIV therapy. Sex. Transm. Infect.
77: 158-173
[Abstract][Full Text]
LUFT, F. C.
(2001). Lactic Acidosis Update for Critical Care Clinicians. J. Am. Soc. Nephrol.
12: S15-S19
[Abstract][Full Text]
Agbenyega, T., Angus, B. J., Bedu-Addo, G., Baffoe-Bonnie, B., Guyton, T., Stacpoole, P. W., Krishna, S.
(2000). Glucose and Lactate Kinetics in Children with Severe Malaria. J. Clin. Endocrinol. Metab.
85: 1569-1576
[Abstract][Full Text]
Forsythe, S. M., Schmidt, G. A.
(2000). Sodium Bicarbonate for the Treatment of Lactic Acidosis*. Chest
117: 260-267
[Abstract][Full Text]
Duke, T.
(1999). Dysoxia and lactate. Arch. Dis. Child.
81: 343-350
[Full Text]
Morten, K. J., Beattie, P., Brown, G. K., Matthews, P. M.
(1999). Dichloroacetate stabilizes the mutant E1{alpha} subunit in pyruvate dehydrogenase deficiency. Neurology
53: 612-612
[Abstract][Full Text]
Adrogue, H. J., Madias, N. E.
(1998). Management of Life-Threatening Acid-Base Disorders- First of Two Parts. NEJM
338: 26-34
[Full Text]
Stacpoole, P. W, Barnes, C. L, Hurbanis, M. D, Cannon, S. L, Kerr, D. S
(1997). Treatment of congenital lactic acidosis with dichloroacetate. Arch. Dis. Child.
77: 535-541
[Full Text]
Previous
